Fig. 5From: Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPDChange from baseline in inspiratory capacity versus placebo and indacaterol (ITT population). Data reported as LS mean difference ± 95 % CI. ***p < 0.001 vs placebo; †p < 0.05 vs indacaterol; ††p < 0.01 vs indacaterol. CI, confidence interval; LS, least squaresBack to article page